General Information of Binding Target of SBP (BTS) (ID: ST00119)
BTS Name
Envelope glycoprotein gp160
Synonyms
Env polyprotein
BTS Type
Protein
Family
HIV-1 env protein family
Gene Name
env
Organism
Human immunodeficiency virus type 1 group M subtype B (isolate HXB2) (HIV-1)
Function
[Envelope glycoprotein gp160]: Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.; [Surface protein gp120]: Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.; [Transmembrane protein gp41]: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
UniProt ID
P04578
UniProt Entry
ENV_HV1H2
PFam
PF00516 ; PF00517
Gene ID
155971
Sequence
MRVKEKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKA
YDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLWDQSLKPCV
KLTPLCVSLKCTDLKNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLD
IIPIDNDTTSYKLTSCNTSVITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCT
NVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPN
NNTRKRIRIQRGPGRAFVTIGKIGNMRQAHCNISRAKWNNTLKQIASKLREQFGNNKTII
FKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTWSTEGSNNTEGSDTITLPCRI
KQIINMWQKVGKAMYAPPISGQIRCSSNITGLLLTRDGGNSNNESEIFRPGGGDMRDNWR
SELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQ
ARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
KLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEL
LELDKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTH
LPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTR
IVELLGRRGWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAI
RHIPRRIRQGLERILL
Sequence Length
856
Synthetic Binding Protein (SBP) Targeting This BTS
SBP Name Highest Status Mechanism Affinity Application Details Ref
DARPin anti-HIV-1 5m3_D12 Research Modulator N.A. Human immunodeficiency virus infection (HIV infection) [ICD-11: 1C62.Z]
SBP Info
[1]
DART anti-HIV Env/CD3 MGD014 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[2]
Fab anti-HIV-1 m0 Research Binder N.A. Cancers [ICD-11: 2D4Z]
SBP Info
[3]
GCN4-based binder anti-HIV-1 C34-GCN4 Research Inhibitor IC50: 16 nM Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[4]
Human VH dAb anti-HIV-1 M36 Research Inhibitor N.A. Human immunodeficiency virus infection (HIV infection) [ICD-11: 1C62.Z]
SBP Info
[5], [3]
Nanobody anti-HIV-1 clone 2H10 Research Binder Kd: 2100 nM Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[6]
scFv anti-HIV-1 1D5C Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[7]
scFv anti-HIV-1 1E7B Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[7]
scFv anti-HIV-1 1G8C Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[7]
scFv anti-HIV-1 3E6B Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[7]
scFv anti-HIV-1 3E7B Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[7]
scFv anti-HIV-1 clone 1-25 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[8]
scFv anti-HIV-1 clone 1-51 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[8]
scFv anti-HIV-1 clone 2-16 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[8]
scFv anti-HIV-1 clone 2-50 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[8]
scFv anti-HIV-1 clone 2-75 Research Binder N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[8]
scFv anti-HIV-1 clone m6 Research Inhibitor N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[9]
scFv anti-HIV-1 clone m9 Research Inhibitor N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[9]
scFv anti-HIV-1 clone X5 Research Inhibitor Kd: 2.5 nM Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[9]
VL dAb anti-HIV-1 D104 Research Inhibitor IC50: 9.7 nM Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[10]
VL dAb anti-HIV-1 F63 Research Inhibitor N.A. Human immunodeficiency virus type 1 infection [ICD-11: XN8LD]
SBP Info
[10]
References
1 Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors. J Virol. 2013 May;87(10):5868-81.
2 MacroGenics. Product Development Pipeline. 2021.
3 Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol. 2008 Oct 10;382(3):779-89.
4 Protein grafting of an HIV-1-inhibiting epitope. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9756-61.
5 Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17121-6.
6 Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies. Elife. 2021 Apr 19;10:e65005.
7 A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C. BMC Biotechnol. 2012 Nov 15;12:87.
8 Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs. Sep-Oct 2009;1(5):462-74.
9 Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol. 2004 Jan 2;335(1):209-19.
10 Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors. AIDS. 2016 Jul 17;30(11):1691-701.